We present 25-year experience with inhibitors in previously untreated patients (PUPs) with severe hemophilia A in Slovakia, where safe factor VIII (FVIII) concentrates have been used since 1990. A prospective study focused on inhibitor incidence in PUPs was established in 1997. Out of a total 61 PUPs born between January 1997 and October 2015, 59 were eligible for evaluation; 50 and 9 were treated with > 20 exposure days (ED) of plasma-derived FVIII (pdFVIII) and recombinant FVIII (rFVIII) products, respectively. In the entire group 13/59 (22%) PUPs developed inhibitors; i.e. 7/50 (14%) and 6/9 (67%) treated with pdFVIII and rFVIII, respectively. Univariate analysis of inhibitor risk factors in patient groups with and without inhibitors showed the rFVIII and serious/ recurrent infections within the first 50 EDs to be associated with inhibitor development (OR of 12.3 [95% CI 2.48-60.83; p ¼ 0.002] and 5.0; [95% CI 1.16-21.9; p ¼ 0.03), respectively]). Also, in multivariate Cox regression analysis, peak treatment ! 5 EDs reached statistical significance. The hazard ratio (HR) was 7.15 (95% CI 1.65-31.36) p ¼ 0.0086 for rFVIII and 4.38 (95% CI 1.02-18.67) p ¼ 0.046 for intensive treatment. Between 1993 and 2015, 21 immune tolerance inductions (ITIs) in 19 inhibitor patients were performed in the two largest hemophilia centers in Slovakia. In all but one ITI courses pdFVIII containing von Willebrand factor (FVIII/VWF) was used with preferred use of high-dose ITI (HD ITI) in high responders (HRs). Complete or partial success was achieved in 17/19 (89.5%) patients. Evaluating only the patients who already completed ITI, the success rate was even higher (15/16; 94%), including 7/7 low responders and
Remarkable progress in hemophilia care in the last two decades in Slovakia with current level of factor VIII (FVIII) supply of 6.5 IU/capita/y and expanding use of prophylaxis in children and adults resulted in significant improvement of quality of life in persons with hemophilia. Today's generation of young hemophiliacs has a real chance to reach the life expectancy of the normal healthy population. Alloantibodies neutralizing FVIII (inhibitors) are a most challenging complication of hemophilia therapy and always cause a big stepback from the advanced care attained. Patients with inhibitor require radical change in treatment strategy, including the use of less effective alternative hemostatic therapy [1] [2] [3] [4] and demanding treatment aimed at eradicating of inhibitors and reinducing the tolerability of FVIII. According to literature, FVIII inhibitors affect approximately 20 to 30% of patients with severe hemophilia A 5, 6 however, most recently a higher incidence in previously untreated patients (PUPs) was reported, approaching even 38 to 42%.
7,8
For many years extensive research has been conducted aimed at unveiling the reason why some patients with severe hemophilia develop inhibitors while a larger proportion of patients remain inhibitor free. Intensive debate is ongoing especially on the impact of the type of FVIII product on inhibitor development and, in particular, on the potential for recombinant FVIII (rFVIII) concentrates to be more immunogenic than plasmaderived FVIII (pdFVIII). [9] [10] [11] [12] [13] [14] Recently, also different immunogenicity of various types of rFVIII has been suggested. 15 However, the reports on the role of treatment products in inhibitor development are often contradictory and remain inconclusive.
7,8,15-17
The only effective treatment for eradication of inhibitors is immune tolerance induction (ITI) with a rate of success of 75 to 94% reported for primary ITI and 44 to 73% for rescue ITI. [18] [19] [20] The role of treatment protocol and optimal dosing regimens is still not clear. However, the first prospective randomized international study (IITI) demonstrated that high-dose protocols used in HR with a good prognosis resulted in reduced bleeding frequency during ITI and faster achievement of success. 21 The high success rates with highdose protocols were observed also in HRs with poor prognostic factors. 19, 22 Several studies demonstrated a potential for FVIII concentrates containing von Willebrand factor (VWF) to achieve successful inhibitor eradication in a high proportion of patients, even in those with poor prognosis. [23] [24] [25] [26] However, recently also rVIII products were shown to be highly effective in ITI, [27] [28] [29] and because of their wider safety margin, they are recommended as the preferred products for ITI by some Authors.
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In Slovakia since 1974 all patients with hemophilia have been registered in the National Hemophilia Registry kept by the National Hemophilia Centre (NHC). Safe pdFVIII concentrates were introduced into hemophilia treatment in 1990, and retrospective surveys comprising a 25-year period showed a cumulative incidence of inhibitors with these products in PUPs with severe hemophilia A ranging between 10.3 and 14% (high-titer inhibitors 7.4%). In 1997 the NHC established a prospective study to monitor systematically inhibitor incidence and potential risk factors in all PUPs with hemophilia A born in Slovakia from this date. Increasing factor supply in the 1990s also permitted introduction of ITI therapy. All patients, either PUPs or previously treated patients (PTPs), developing clinically relevant inhibitors after 1990 were indicated for ITI. In the present article we report the interim results of this ongoing prospective inhibitor study and our experience with ITI performed in patients with inhibitors in the period 1993-2015.
Materials and Methods

Prospective Study on Inhibitors Incidence in PUPS
Patients
All consecutive patients with hemophilia A born in Slovakia since 1997 have been involved in a prospective, open-label nationwide ongoing study focused on inhibitor development in PUPs. Inhibitor status was tested every 4 to 5 exposure days (EDs) during the first 20 EDs, then every 10 and 20 EDs up to 50 and 150 EDs, respectively. Potential risk factors for developing inhibitor were followed: severity of hemophilia, F8 gene mutation, family history of inhibitors, age at the first bleeding and first therapy with FVIII, reason for the first therapy, vaccination concurrent with FVIII, and the type of product (pdFVIII, rFVIII). Severe bleeding, surgery, red blood cells transfusion, severe infection, and FVIII replacement during 3 to 4 days and ! 5 days within the first 50 ED were also recorded.
Treatment with FVIII Concentrates
Between 1997 and 2008 exclusively pdFVIII concentrates were used with a majority comprising FVIII/VWF products. In 2004 prophylaxis in children was introduced and vaccination without concurrent FVIII was preferred. rFVIII products started to be used in PUPs in 2008, and the choice of product (pdFVIII or rFVIII) was based on the discussion with parents and their preference. Intensive treatment was defined as administration of FVIII during ! 5 consecutive days. Only severe hemophilia A showed higher incidence of inhibitors in patients treated with rFVIII and those with intensive therapy within first 50 EDs. However, our experience is limited to small numbers of patients; thus, our results must be interpreted cautiously. High success rate of the ITI in our inhibitor patients has been achieved with FVIII/VWF concentrates and preferred use of HD ITI in HR patients. patients who received > 20 EDs of FVIII and patients developing inhibitors before reaching 20 EDs were eligible for the evaluation of inhibitor incidence.
Laboratory Methods
Both standard Bethesda method and Nijmegen modification were used for inhibitor testing and the titers of > 0.6 BU/mL and > 0.5 Nijmegen BU/mL (NBU/mL) were considered as positive. The diagnosis of inhibitor was based on two consecutive positive results. F8 genotyping was performed by standard techniques, such as long-distance polymerase chain reaction (PCR), multiple ligation-dependent probe amplification (MLPA), and DNA sequencing methods. Inversion of intron 22 and intron 1, large deletions, and nonsense mutations were classified as high-risk mutations, and small deletions/insertions and missense mutations as low-risk mutations for inhibitor development.
Immune Tolerance Therapy in Patients with Inhibitors
Patients and Immune Tolerance Induction Protocols
Since 1993 all consecutive ITI courses performed in the two largest hemophilia comprehensive care centers (HCCC), the NHC in Bratislava and the Regional HCCC in Banska Bystrica, have been evaluated. The data on the history of inhibitor development, the course of ITI, and the treatment outcomes are precisely recorded. 
Laboratory Monitoring
Inhibitor status was tested frequently upon the start of ITI to capture anamnestic peak titer and afterwards once monthly. After reduction of inhibitor < 1 NBU/mL in vivo recovery was monitored, and when negativity of inhibitor was achieved, investigation of FVIII pharmacokinetics was performed to determine FVIII clearance and half-life by standard method.
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Definition of Immune Tolerance Induction Outcome
Complete success (CS) was defined as negative inhibitor titer confirmed by both methods (< 0.6 BU/mL and < 0.5 NBU/ mL), in vivo recovery > 66% and half-life > 6 hours. Partial success (PS) was determined by negative inhibitor without full normalization of recovery or half-life, however, enabling prophylaxis with FVIII, in the absence of anamnestic response. Treatment failure was defined as inability to eradicate inhibitor and install an effective prophylaxis within 36 months of ITI. Reappearance of inhibitor and/or treatment ineffectiveness in patients with previous CS and PS was classified as an inhibitor relapse.
Ethical Considerations
Both studies were conducted in accordance with the ethical principles according to the Declaration of Helsinki with the informed consent signed by patients and/or parents. 
Statistical Analysis
Prospective Study on Inhibitor Incidence and Risk Factors
Ninety patients with hemophilia A were born in Slovakia between January 1997 and October 2015, 61 with severe, 17 moderate, and 12 mild hemophilia. Fifty-nine of 61 patients with severe hemophilia A were treated with FVIII concentrates and were eligible for evaluation (►Table 1). All patients used the same brand of product up to at least 100 EDs or until development of inhibitor, whichever came first. All inhibitors developed within 35 EDs. Forty-six patients did not develop an inhibitor, of them 11% and 80% had > 50 and > 100 EDs, respectively. Ten patients switched from pdFVIII to rFVIII after > 100 EDs and they were analyzed in the pdFVIII group. In the given time period 13/59 (22%) PUPs with severe hemophilia A developed an inhibitor at a median age of 17 months (IQR 14-20) after 18 EDs (12-25 EDs), with historical peak of inhibitor 7.5 BU/mL (range 1.0-500 BU/ mL). Eight (61.5%) and five (38.5%) inhibitor patients were high and low responders, respectively. 
Treatment Product and Inhibitor Development
Out of the 50 PUPs initially treated with pdFVIII, 7 (14%) developed inhibitor of whom 4 patients had a high-titer inhibitor. In the group of nine PUPs treated with rFVIII six (66.7%) patients developed inhibitors of whom four patients had high-titer inhibitors. None of the 10 patients switching from pdFVIII to rFVIII developed inhibitor. There was no significant difference in the distribution of putative confounders between pdFVIII and rFVIII treatment groups (►Fig. 2), except for a higher proportion of the family history of inhibitor in the rFVIII group: 4/9; 44.4% versus 6/50; 12% (OR ¼ 5.86; 95% CI 1.22-28.12; p ¼ 0.03). However, two PUPs born in 2012 were from one hemophilia family and they had negative history before they began therapy with rFVIII. The number of patients with > 50 EDs was significantly lower in the rFVIII group than in pdFVIII group due to a higher proportion of inhibitors within first 35 EDs. A subanalysis of 24 patients treated from 2008 onward, that is, when rFVIII and pdFVIII were concomitantly used, showed inhibitors development in 6/9 (66.7%) patients treated with rFVIII (4 HRs) versus 2/15 (13.3%) patients treated with pdFVIII concentrates (1 HR). ►Table 3 shows the characteristics of inhibitors in patients treated with rFVIII and pdFVIII. The first bleeding and first treatment were recorded earlier in the pdFVIII inhibitor group, whereas the proportion of HRs and the inhibitor titers were higher in the rFVIII group (the difference was not statistically significant). As to the type of rFVIII, inhibitors developed in 4/4 PUPs treated with the second-generation full-length rFVIII; one of three patients treated with the third-generation rFVIII and one of two PUPs with a second-generation B-domain deleted FVIII (BDD FVIII). All but one inhibitor patient, who had historical peak of 500 BU/mL and is still waiting for his inhibitor level to drop below 10 BU/mL, underwent ITI.
Immune Tolerance Induction
Between 1993 and 2015, 21 ITI treatments were performed in 19 severe hemophilia A patients with inhibitors in the NHC in Bratislava (15 primary and 3 rescue ITIs) and in regional HCCC in Banska Bystrica (3 primary ITIs). ►Table 4 summarizes the main clinical characteristics of patients and ITI procedures. Six patients were PTPs who developed inhibitors after the switch from cryoprecipitate to purified FVIII at the median age 20 years (IQR 14-36) after a median of 28 exposures to FVIII concentrate . In one patient, inhibitors developed after major surgery and successfully eradicated with ITI; however, the patient had two relapses, each after the next consecutive operation. The PUPs treated exclusively with FVIII concentrates developed inhibitor earlier (median age 1.5 years; IQR 1.4-1.9 years) after 18 EDs (12-25 EDs). In one PUP high-titer inhibitor developed at the age of 1.5 years and was eradicated by 36 months ITI in another center. Inhibitor relapsed at age 10 years and the patient underwent a rescue ITI in our center at the age of 17 years. Patient with concomitant Down syndrome and Fallot tetralogy with early perspective of major cardiac surgery was put on early prophylaxis with rFVIII at the age of 4 months. He developed low-titer inhibitor after 6 EDs. He was treated with high doses of FVIII, which successfully covered also emergency heart surgery. However, ITI was not completed as he died on day 10 postsurgery due to heart failure.
In the entire group, a total of 11 patients were HRs, of whom 9 were treated with HD ITI and 2 with historical titer 20 BU/mL and negative pre-ITI titer were treated with LD ITI. Out of eight LRs, seven were treated with LD ITI and one with HD ITI. As shown in ►Table 5, pdFVIII/VWF concentrates were used in all but one ITI therapy. CS was achieved in 15/19 (79%) patients and PS in one (5.3%). Treatment failure in patient 10 was supported by poor prognostic factors and patient's noncompliance. HD ITI is ongoing in two HRs, including the patient with PS and still subnormal FVIII halflife.
Rescue therapy was used for inhibitor relapses in two patients. In patient 6 the LD ITI was given concomitantly with a standard cycle of rituximab (four doses of 375 mg/m 2 )
with a CS and the sustained remission after the first and second treatment with rituximab, respectively. Despite delayed rescue, ITI patient 7 achieved CS after 24 months of HD ITI. Patient 13 achieved an early PS after 3 months of ITI; however, each of the three infection complications of Port-ACath resulted in significant inhibitor increase with a peak of even 70 BU/mL despite continuing ITI. Addition of rituximab to the ITI at the month 40 resulted in complete inhibitor eradication with normalization of FVIII pharmacokinetics. Port-A-Cath was used in eight patients (age range 1.5-6.0 years). In four patients 1 to 3 removal procedures and reimplantations were required, in two of them Port-A-Cath was switched for tunneled catheter Broviac (Bard Access Systems Inc.).
We analyzed the ITI outcome with regard to inhibitor titer and treatment regimen. All patients with pre-ITI inhibitor titer < 5 BU/mL (range 0-3.5 BU/mL) achieved a CS, while the ITI failed in one patient with pre-ITI titer of 10.8 BU/mL. The median time to negativity of inhibitor and to CS was significantly shorter in LR than in HR: 2.8 (IQR 2-3) versus 6.0 months (2-11.3), p < 0.001; and 7.5 (IQR 3-6) versus 20.0 months (13.5-24.0), p < 0.001, respectively. The LD ITI resulted in the inhibitor negativity and CS earlier than HD ITI. However, the HD ITI was used in patients with less favorable prognosis (HRs and poor prognosis factors). Despite this, the success rate in HD ITI group was 5/6 (83.3%) when all completed HD ITI treatments were evaluated.
Discussion
Concomitantly with the progress in hemophilia care including an improved access to replacement therapy and prophylaxis, we are witnessing an increase in the incidence of inhibitors, today the most challenging complication of hemophilia therapy. Increased morbidity, less effective hemostatic therapy with bypassing agents, limited access to prophylaxis, and demanding ITI inevitably bring a huge burden on patients, their families, and hemophilia treaters as well. The situation is further aggravated by the fact that this complication arises mostly in the youngest children with severe hemophilia soon after initiation of therapy. Several potential risk factors for inhibitor development has been recognized and several models for inhibitor prediction based on the combinations of these risk factors were developed. 34, 35 Since so-called "nonmodifiable" genetically determined risk factors 5,36 of inhibitors cannot be avoided, to prevent an impact of "modifiable" environmental and treatment-related risk factors, various preventive approaches were recommended such as early prophylaxis, avoidance of early surgery and intensive treatment with high doses of factor concentrate, vaccination without concomitant factor administration, etc. [36] [37] [38] However, an early or intensive treatment and emergency surgery cannot be fully avoided in all patients and early prophylaxis is not feasible for all; thus the potential role of the type of FVIII product in inhibitor development becomes increasingly important. In patients using rFVIII cumulative inhibitor, incidence of 30% and even higher has been reported, with high-titer inhibitors reaching 19 to 24%. 7, 8, 17, 39 Recently several studies pointed on a higher immunogenicity of some brands of rFVIII. 10, 11, 14, 49 as well as with the situation in our country.
The differences in the incidence of inhibitors in different studies are usually attributed to the frequency of inhibitor testing, laboratory method used, and/or the different design of the studies. Nevertheless, the probability of overlooking the clinically relevant inhibitors in experienced center is extremely low and more frequent testing only improves revealing of very low-titer or transient inhibitors. Our prospective nationwide inhibitor study showed in 59 PUPs born Abbreviations: BU/mL, Bethesda unit per milliliter; ED, exposure days; ITI, immune tolerance induction; pdFVIII, plasma-derived FVIII; PTPs, previously treated patients; PUPs, previously untreated patients; rFVIII, recombinant FVIII. a Median (interquartile range). The major limitation of our study is the small sample size. On the other hand, the advantage is a homogenous patient population from one country with similar treatment conditions. The occurrence of eight new, clinically relevant inhibitors in a 7-year period, without any change in treatment policy other than type of product, is a reality pointing out a major safety issue in hemophilia therapy. In theory, to achieve an incidence of 14% as observed with pdFVIII, another 33 patients treated with rFVIII would have to remain free of inhibitor. As reported by Franchini et al, because of still vivid memory of the immense tragedy of human immunodeficiency virus (HIV) infection transmitted by plasma-derived nonvirally inactivated concentrates, the choice of the type of product in Italy is still dictated by safety concerns rather than immunogenicity of products. 53 However, Slovakia has not been confronted with HIV infection as none of our hemophiliacs was infected, so an increasing incidence of inhibitors is perceived as a major safety issue. Tremendously challenging management of inhibitors, especially in little children, with potential risk of the ITI failure has an impact on the product choice. In the current era of availability of virologically safe pdFVIII concentrates, most of our hemophilia treaters are reluctant to put the PUPs on rFVIII products. This has been also a major reason for so far low number of subjects in our rFVIII study group. The only effective treatment for eradication of inhibitors is ITI. Depending on the protocol, success can be achieved in 60 to 90% of patients. 54 Several centers demonstrated a potential for FVIII concentrates containing VWF to achieve a high rate of successful inhibitor eradication. [22] [23] [24] [25] [26] 60 In vitro and in vivo experiments showed that pdFVIII/VWF provides better protection against inhibitor neutralization than rFVIII, which results in prolonged persistence of FVIII in the circulation. 61 Most of current guidelines for ITI commonly recommend the switch for FVIII/VWF concentrates in patients who failed to achieve ITI success with rFVIII as well as for the rescue ITI.
30,31,54,62
Our study included all consecutive patients with FVIII inhibitors undergoing ITI in two HCCC and showed a high success rate in inhibitor eradication. The CS and PS was achieved in 17/19 (89.5%) patients, including four patients with poor prognosis factors. Evaluating only the patients who completed ITI, the success rate was even higher (15/16; 94%), comprising 7/7 LRs and 8/9 HRs.
High success rate in our study was associated with (1) an early start of ITI in most patients; (2) low historical and pre-ITI inhibitor titers; (3) preference of the HD protocol for the high responders; and (4) possibly to preferred use of FVIII/ VWF concentrates. Our ITI policy is based on the experience with FVIII/VWF in the ITI from other centers. inhibitors, is a matter of intensive debate. The use of rituximab is mostly supported by several case reports or small series, with a success rate ranging between 25 and 53%. [63] [64] [65] [66] [67] Several ITI guidelines recommend this treatment as a second-line therapy after the ITI failure or in patients refractory to ITI. 30, 31, 55, 62 We used rituximab in two patients as an adjuvant to the rescue ITI therapy with a good response and CS.
Conclusion
We present 25-year experience with FVIII inhibitors in patients with severe hemophilia A. Our prospective study shows that rFVIII products are significant risk factors for inhibitor development in our PUPs with severe hemophilia A. We realize that because of a small sample size in our study, the power of statistical evaluation is limited and the results must be interpreted with a caution. However, several new inhibitors observed in a recent period resulting in increased demands on the resources for therapy reflects a real world, which cannot be ignored. Our experience with ITI using FVIII/VWF concentrates and proper use of high-dose protocol showed favorable results with a high success rate. Recombinant products undoubtedly represent a major progress in the treatment of hemophilia, and new-generation, longer-acting recombinant factors will probably replace current drugs soon. With regard to this fact it is of paramount importance to have the products with a wider margins of safety in terms of inhibitor development, which will be safe in all situations of hemophilia management and not only in "ideal" low-risk patients.
